Pre- and Post-Treatment Investigation of B12 and Folic Acid (Folate) Levels in Patients Receiving Antiepileptic (Anticonvulsant) Treatment for Fibromyalgia: Retrospective Study

Launched by GAZIOSMANPASA RESEARCH AND EDUCATION HOSPITAL · Jun 5, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at how treatment with certain medications for fibromyalgia—specifically, antiepileptic drugs—affects levels of vitamin B12 and folic acid in patients. Fibromyalgia is a condition that causes widespread pain, fatigue, and problems with sleep and thinking. The trial will examine patients aged 18 to 75 who have been diagnosed with fibromyalgia and have had their vitamin B12 and folic acid levels tested. To participate, they should not be receiving vitamin B12 or folic acid treatment, and they should not have diabetes or serious liver or kidney issues.

Participants in this study can expect that their vitamin levels will be checked before and after they start taking antiepileptic medications. The goal is to understand if these medications might lead to deficiencies in these important vitamins, which could help improve treatment plans for fibromyalgia in the future. It’s important to note that the trial is still in the planning stages and is not yet recruiting participants.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients aged 18-75 years who have been diagnosed with fibromyalgia, whose vitamin B12 and folic acid levels have been analysed, who do not receive vitamin B12 and folic acid treatment, and who do not have diabetes mellitus, liver and kidney failure
• Exclusion Criteria:
• • Patients receiving vitamin B12 and folic acid therapy at the time of antiepileptic (anticonvulsant) drugs initiation, patients with hepatic and renal insufficiency